BioStock is joined by SynAct Pharma’s CSO, Thomas Jonassen, and CBO, Mads Bjerregaard, for an update on the company’s "dual development strategy". With the phase IIb ADVANCE study in rheumatoid arthritis and the phase II RESPIRE study in respiratory viral infections running in parallel, the company is approaching key milestones over the next 12 to 18 months. In the interview, the duo discusses the potential of the drug candidate resomelagon as a non-immunosuppressive therapy, as well as the significant commercial opportunities that would open up following positive trial results. Furthermore, we learn more about the current interest from potential partners and what to expect from the company's Capital Markets Day in Stockholm on 11 March.